very low density lipoprotein receptorGenealiases: CAMRQ1 · CARMQ1 · CHRMQ1 · VLDL-R · VLDLRCH
Q-omics provides the consensus-scored VLDLR profile across patient tissues and cancer cell-line models. VLDLR expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, VLDLR is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, VLDLR RNA expression shows 18,918 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where VLDLR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VLDLR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VLDLR survival associations across molecular data types. VLDLR RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VLDLR RNA expression–survival associations across cancer types. High VLDLR expression shows unfavorable associations in UVM, BLCA and BRCA, but favorable associations in SCLC, KIRC and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for VLDLR RNA expression.
This table summarizes VLDLR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VLDLR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VLDLR shows lower tumor expression in THCA, LUAD, COAD and BLCA and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher VLDLR RNA expression in tumor versus normal tissue (log2 FC = +0.945, t-test p < 0.001).
This table shows molecular features associated with VLDLR in patient tissues and cancer cell lines. In patient samples, VLDLR shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, VLDLR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
